In conclusion, this study identifies the MIF-CD44 axis as a pivotal driver of MASLD-associated PDAC liver metastasis and provides a strong rationale for its therapeutic targeting. This evidence concerns the gene CD44 and metabolic dysfunction-associated steatotic liver disease.